RELAPSED NON HODGKIN LYMPHOMA
Clinical trials for RELAPSED NON HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED NON HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED NON HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for tough blood cancers: early trial of Bcl-2 blocker begins
Disease control OngoingThis study tests a new drug called BGB-21447 for people with certain blood cancers (like lymphoma and leukemia) that have returned or not improved after prior therapy. The main goals are to find the safest dose and see if the drug can shrink tumors. About 112 participants will re…
Matched conditions: RELAPSED NON HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated May 26, 2026 06:57 UTC
-
Engineered immune cells take on Hard-to-Treat blood cancers
Disease control OngoingThis early-stage study tests a new cell therapy called ANCHOR cells for people with B-cell lymphoma or leukemia that has returned or not responded to standard treatments. The cells are made from a healthy donor's immune cells and are modified to better recognize and attack cancer…
Matched conditions: RELAPSED NON HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated May 26, 2026 06:53 UTC
-
Can a quick radiation boost make CAR t work better for tough lymphomas?
Disease control OngoingThis early-phase study looks at whether giving low-dose radiation before CAR T-cell therapy is practical and safe for people with B-cell lymphoma that has returned or not responded to treatment. About 33 adults will receive radiation to shrink tumors while waiting for their CAR T…
Matched conditions: RELAPSED NON HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: University of Nebraska • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
New drug duo takes on tough lymphoma
Disease control OngoingThis early-phase trial tests the safety and correct dose of combining two cancer drugs, loncastuximab tesirine and venetoclax, for adults with relapsed or refractory B-cell non-Hodgkin lymphoma. About 23 participants will receive the combination to see how well it is tolerated an…
Matched conditions: RELAPSED NON HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Paolo Caimi, MD • Aim: Disease control
Last updated May 19, 2026 12:00 UTC
-
15-Year safety check for caribou cell therapy patients
Knowledge-focused ENROLLING_BY_INVITATIONThis study tracks 150 people who previously received Caribou cell therapy for blood cancers like lymphoma or leukemia. The goal is to watch for long-term side effects and safety issues over 15 years. No new treatment is given—just regular check-ups to see how patients are doing.…
Matched conditions: RELAPSED NON HODGKIN LYMPHOMA
Sponsor: Caribou Biosciences, Inc. • Aim: Knowledge-focused
Last updated May 26, 2026 06:44 UTC